Overview

Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

Status:
RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
Phase:
PHASE2
Details
Lead Sponsor:
Neurocentria, Inc.